Two papers, an original article and follow up data from a randomized clinical trial on the use of rituximab for new-onset generalized Myasthenia Gravis (MG) has been reviewed. The studies assess the effectiveness and safety of rituximab over several years, concluding that early exposure to the treatment may offer sustained benefits in disease activity and reduce the need for rescue treatments, despite raising concerns about infection risk.